CONMED (CNMD) Q2 2026 earnings review
The $0.21 Illusion: Strong Margins Mask a Subtle Underlying Guidance Cut
CONMED delivered a massive 300 basis point expansion in Adjusted Gross Margin and raised full-year EPS guidance. But investors need to read the fine print: the $1.38 Adjusted EPS included a $0.21 one-time benefit from IEEPA tariff refunds. Without it, EPS would have been $1.17, essentially stable year-over-year. Management raised the midpoint of FY26 EPS guidance by only $0.16—meaning the underlying operational profit forecast was actually cut by roughly $0.05. The strategic exit from the GI business is successfully driving gross margins higher, but domestic revenue growth is decelerating to a concerning 2.5% organic rate.
🐂 Bull Case
The strategic divestiture of the lower-margin GI business is translating directly to the bottom line. Adjusted gross margin surged to 59.5% (up from 56.5% a year ago), validating management's strategy to focus on core, high-margin platforms.
Orthopedics constant currency growth is accelerating, posting 6.8% this quarter compared to a sluggish 0.8% a year ago. The severe supply constraints of 2024 and early 2025 appear definitively resolved.
🐻 Bear Case
Management raised FY26 adjusted EPS guidance, but the raise is entirely fueled by a $0.21 Q2 tariff refund. Backing this out, the core operational outlook for the rest of the year actually worsened.
While international markets surged 9.9% organically, U.S. organic growth decelerated to a tepid 2.5%. If the U.S. market cannot accelerate, hitting long-term growth targets will be mathematically difficult.
⚖️ Verdict: ⚪
Neutral. The structural margin improvement from exiting GI is highly encouraging, but the smoke-and-mirrors guidance update and decelerating domestic top-line demand warrant caution.
Key Themes
The Headline Contradiction: Guidance Raise vs. Tariff Refund
Management's press release headlines an updated and increased FY26 guidance. However, the data contradicts the positive narrative. The FY26 Adjusted EPS guidance midpoint was raised from $4.375 to $4.54 (a $0.165 increase). Yet, Q2 results included a $0.21 unexpected benefit from IEEPA tariff refunds. Mathematically, this means management lowered their core operational earnings expectation for the second half of the year by approximately $0.04 to $0.05. Furthermore, the organic constant currency revenue growth guidance midpoint was subtly trimmed from 5.75% to 5.50%.
GI Divestiture Radically Transforms Margins
The intentional decision to exit the gastroenterology business is paying massive dividends on the margin line. Adjusted Gross Margin accelerated to 59.5% in 26Q2, up 300 basis points year-over-year. Adjusted Operating Margin similarly expanded from 15.7% to 18.2%. The company is trading empty revenue calories for highly profitable core surgical volumes.
Orthopedics Back on the Offensive
Orthopedics revenue growth is accelerating. Segment sales increased 6.8% on a constant currency basis, a vast improvement from the 0.8% growth seen in 25Q2. This confirms that the severe sports medicine supply chain backorders that plagued the company throughout 2024 and 2025 are resolved, allowing the sales force to actively take back market share.
AirSeal Indicated for Intuitive's da Vinci 5
Technology integration continues to be a core driver. On July 22, CONMED announced that its AirSeal Robotic Solution is now indicated for use with Intuitive's 8mm hex cannulas on the new da Vinci 5 platform. With DV5 adoption ramping up globally, securing this indication ensures AirSeal remains the gold standard for low-pressure insufflation in next-generation robotic procedures.
Domestic Market Deceleration
While the overall organic constant currency growth was a healthy 6.0%, it was heavily carried by International markets (+9.9%). Domestic organic growth was a sluggish +2.5%. The U.S. is CONMED's largest market, and a failure to re-accelerate domestic general surgery and orthopedics represents a significant risk to the FY26 targets.
Capital Equipment Sales Reversing
Capital Products revenue is reversing its prior negative trend. In 25Q2, capital equipment collapsed by 15.6% CC. In 26Q2, it grew 7.6% CC organically. Because capital placements (like AirSeal and Buffalo Filter generators) drive high-margin, recurring single-use disposable revenue, this rebound is a critical leading indicator for future cash flow.
Leadership Roulette Continues
CONMED has appointed John E. Gallagher as the new CFO, effective July 15. This follows the abrupt departure of the prior 8-year veteran CFO earlier in the year. With debt refinancing on the horizon and complex divestiture accounting ongoing, stabilizing the C-suite is paramount for investor confidence.
Macro FX Headwinds Persist
Despite earlier hopes for a normalized currency environment, foreign exchange remains a drag. FX negatively impacted reported net sales by 0.5% (roughly $1.7 million) in the quarter. Management continues to model a 0.5% headwind into the full-year 2026 sales guidance.
Other KPIs
Accelerating. Up from 56.5% in 25Q2. The divestiture of the lower-margin GI business is having an immediate and profound impact on the cost profile, driving profitability higher despite flattish overall reported revenue.
Decelerating on a reported basis (-0.9% YoY) but up 8.2% organically in constant currency. This segment represents 86% of total revenue and is the core recurring engine of the business.
Guidance
Stable. The midpoint of $4.54 implies a 1.1% decline versus FY25's $4.59. While optically raised from prior guidance ($4.30-$4.45), the entire raise is attributable to a $0.21 Q2 tariff refund, indicating underlying operational expectations actually decelerated slightly.
Stable. The midpoint of $1.365B implies roughly flat reported growth (-0.7% YoY) largely due to the GI divestiture. The range was narrowed and slightly tweaked from the prior $1.350-$1.375 billion.
Decelerating. Management tweaked the range from the previous 5.0% - 6.5%. While excluding GI sales, the reduction of the top-end implies a slightly more cautious outlook for underlying volumes in the second half of the year.
Key Questions
The Guidance Discrepancy
You recorded a $0.21 benefit from tariff refunds this quarter, but only raised the midpoint of your full-year EPS guidance by $0.165. Where is the ~$0.05 of underlying operational deterioration coming from?
Domestic Demand Softness
Domestic organic growth was only 2.5% this quarter, significantly lagging the 9.9% seen internationally. Is this a function of hospital capital constraints, competitive losses in General Surgery, or delayed recovery in Orthopedics?
da Vinci 5 Attachment Rates
With AirSeal now officially indicated for the da Vinci 5's 8mm hex cannulas, what specific attachment rate changes are you observing as hospitals transition from the Xi to the DV5 platform?
CFO Transition Strategy
With John Gallagher taking over as CFO next month, what are his immediate mandates regarding the impending debt refinancing and capital allocation strategy?